Perspective Therapeutics, Inc.
HealthcareAMEX:CATX · New York Stock Exchange American
-$0.02 today
Vol 0.94M · Avg 1.44M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$103.1M -30.1% | -$79.3M -70.5% | -$46.5M -217.0% | -$14.7M -101.7% | -$7.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.3M +41.0% | $2.3M +143.8% | $946.0K +175.0% | $344.0K +38.7% | $248.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$793.0K +62.2% | -$2.1M +20.9% | -$2.7M -57.6% | -$1.7M | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $9.0M +66.4% | $5.4M +44.1% | $3.7M +178.1% | $1.3M +23.6% | $1.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $1.7M | $0 -100.0% | $2.3M +579.3% | $338.0K +118.3% | -$1.9M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$32.0K -103.1% | $1.0M +346.2% | -$426.0K -186.9% | $490.0K +21.0% | $405.0K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 -100.0% | $11.0K -96.9% | $359.0K +336.2% | -$152.0K +94.3% | -$2.7M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $147.0K -92.2% | $1.9M +19.3% | $1.6M | $0 -100.0% | $236.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $1.6M | $0 -100.0% | $779.0K | $0 -100.0% | $182.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $7.5M -86.4% | $55.4M +951.8% | $5.3M +1015.7% | $472.0K +513.0% | $77.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$82.5M -350.9% | -$18.3M +50.4% | -$36.9M -203.3% | -$12.2M -57.9% | -$7.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$12.7M +76.6% | -$54.4M -4975.9% | -$1.1M -255.0% | -$302.0K -13.5% | -$266.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 -100.0% | $2.7M | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$119.8M +50.8% | -$243.5M | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $173.9M | $0 -100.0% | $22.8M | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$135.0K -100.2% | $79.0M +438950.0% | -$18.0K +100.0% | -$57.4M -318655.6% | -$18.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $41.2M +118.8% | -$218.9M -998.3% | $24.4M +142.3% | -$57.7M -20209.2% | -$284.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$52.0K | $0 +100.0% | -$68.0K | — | — | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $10.4M -96.2% | $275.8M +75671.2% | $364.0K | $0 -100.0% | $56.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $289.4M +59078.9% | $489.0K +773.2% | $56.0K | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $10.3M -96.4% | $289.4M +36764.3% | $785.0K +1301.8% | $56.0K +0.0% | $56.0K | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 -100.0% | $61.9M | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$31.0M -159.3% | $52.2M +211.8% | -$46.7M -25733.0% | $182.0K +102.3% | -$7.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$95.2M -31.0% | -$72.7M -91.4% | -$38.0M -204.5% | -$12.5M -56.4% | -$8.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Electromed, Inc.
AMEX:ELMD
$307.52M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Solana Company
NASDAQ:HSDT
$89.92M
Nyxoah S.A.
NASDAQ:NYXH
$55.05M
SEC Filings
Recent regulatory filings
No filings found.
Does CATX generate free cash flow?
Perspective Therapeutics, Inc. (CATX) generated -$95,233,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does CATX produce?
Operating cash flow was -$82,484,000.00, before capital expenditures of $12.75M.
Explore More
Continue the stock analysis
Jump to another research area for this company.